Document Detail


The effects of trimetazidine on p-wave duration and dispersion in heart failure patients.
MedLine Citation:
PMID:  19170914     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: P-wave duration and dispersion (PWD) have been shown to be noninvasive predictors for development of atrial fibrillation. Thus, it may be possible to attenuate atrial fibrillation risk through normalization of P-wave duration and dispersion. Trimetazidine, a metabolic modulator, has been reported to improve cardiac function in heart failure (HF) patients. METHODS: Thirty-six HF patients being treated with angiotensin inhibitors, carvedilol, spironolactone, and furosemide were prescribed trimetazidine, 20 mg three times a day. Electrocardiographic and echocardiographic examinations were obtained before and 6 months after addition of trimetazidine in HF patients and 36 healthy control group patients having normal echocardiographic examination. RESULTS: Maximum P-wave duration (Pmax) (106.7 +/- 15.8 vs. 91.7 +/- 12.7 ms) and PWD (57.2 +/- 15.4 vs. 37.9 +/- 16.7 ms) were significantly longer in HF patients compared to the control group. There were significant correlations of Pmax and PWD with left atrial diameter (r = 0.508, P = < 0.001 and r = 0.315, P = 0.029), left ventricular ejection fraction (LVEF) (r = 0.401, p = 0.005 and r = 0.396, P = 0.005), deceleration time (r = 0.296, P = 0.032 and r = 0.312, P = 0.035), and isovolumetric relaxation time (r = 0.265, P = 0.038 and r = 0.322, P = 0.015). There were significant improvements in LVEF (32.7 +/- 6.5% to 37.2 +/- 5.5%, P = 0.036), left atrial diameter (41.5 +/- 6.7 to 40.3 +/- 6.1 mm, P < 0.001), and Pmax (106.7 +/- 15.8 to 102.2 +/- 11.5 ms, P = 0.006) and PWD (57.2 +/- 15.4 to 48.9 +/- 10.1 ms, P < 0.001) during follow-up. CONCLUSIONS: Trimetazidine added to optimal medical therapy in HF may improve Pmax and PWD in association with improved left ventricular function. Longer-term and larger studies are necessary to evaluate whether these findings may have clinical implications on prevention of atrial fibrillation.
Authors:
Yilmaz Gunes; Mustafa Tuncer; Unal Guntekin; Serkan Akdag; Hasan Ali Gumrukcuoglu
Related Documents :
20854974 - Usefulness of intravenously administered fluid replenishment for detection of patent fo...
10793994 - A pilot study of radiotelemetry for continuous cardiopulmonary monitoring of patients a...
15136494 - Left septal atrial flutter: electrophysiology, anatomy, and results of ablation.
7388424 - Treatment of accidental hypothermia: a prospective clinical study.
9474674 - Prospective evaluation of the length of the lower common pathway in the differential di...
7902484 - Mineralisation defects with pamidronate therapy for paget's disease.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  32     ISSN:  1540-8159     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-03-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-44     Citation Subset:  IM    
Affiliation:
Cardiology Department, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey. yilmazleman@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chemotherapy, Adjuvant / methods
Electrocardiography / drug effects*
Female
Heart Failure / diagnosis*,  prevention & control*
Heart Rate / drug effects*
Humans
Male
Middle Aged
Trimetazidine / administration & dosage*
Vasodilator Agents / administration & dosage
Ventricular Dysfunction, Left / diagnosis*,  prevention & control*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 5011-34-7/Trimetazidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and be...
Next Document:  Strategies to minimize the risk of esophageal injury during catheter ablation for atrial fibrillatio...